TCT 2021
TCT 2021
Advertisement
Rebecca AraujoAtherosclerotic Disease | April 11, 2023
A study presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 Annual Meeting investigated long-term ...
Read More
Rebecca AraujoAtherosclerotic Disease | April 11, 2023
In a study, researchers utilized the ADVANCE Registry to investigate the relationship between body mass index (BMI) and ...
Rebecca AraujoTCT 2021 | April 12, 2023
A study presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2021 Annual Meeting reported the final ...
Jessie Holtzman, MDCardioNerds | April 11, 2023
Data presented at the Transcatheter Cardiovascular Therapeutics (TCT2021) conference and published in the New England ...
Rob DillardTCT 2021 | February 11, 2021
A significant portion of patients with chronic graft-versus-host disease (cGVHD) live with severe and prolonged ...
Rob DillardTCT 2021 | August 29, 2023
Clinically significant graft-versus-host disease (CSGVHD) in children is associated with considerably reduced survival, ...
Rob DillardTCT 2021 | July 5, 2023
Pneumatosis and/or perforation represents a rare, yet extremely serious complication of acute gastrointestinal (GI) ...
Rob DillardTCT 2021 | February 11, 2021
Patients with chronic graft-versus-host disease (cGVHD) are adversely impacted in terms of employment and income, ...
Rob DillardTCT 2021 | February 9, 2021
Fecal microbiota transplant (FMT) is a relatively safe and viable treatment option for acute gut graft-versus-host ...
Rob DillardTCT 2021 | July 5, 2023
Less than half of patients in low-to-middle-income countries with severe chronic graft-versus-host disease (cGVHD) who ...
Rob DillardTCT 2021 | February 9, 2021
The effect of graft-versus-host lymphoma (GVL) is correlated with graft-versus-host disease (GVHD), according to a study ...
Rob DillardTCT 2021 | April 20, 2023
Low-intensity immunosuppressive therapy for chronic graft-versus-host disease (cGVHD) is effective, according to a study ...
Rob DillardTCT 2021 | February 9, 2021
The use of post-transplant cyclophosphamide (PTCy) notably attenuates the risk of acute graft-versus-host disease ...
Rob DillardTCT 2021 | February 9, 2021
Insufficient risk-stratifying graft-versus-host disease (GVHD) biomarkers may lead to failure of prophylactic therapy, ...
Rob DillardTCT 2021 | September 26, 2023
Conditioning regimen intensity has a significant impact on clinical outcomes following allogeneic hematopoietic cell ...
Rob DillardTCT 2021 | August 23, 2023
Platelet and red blood cell (RBC) transfusions are associated the development of acute graft-versus-host disease ...
Rob DillardTCT 2021 | February 7, 2021
The clinical impact of human leukocyte antigen (HLA) disparities appears to vary among patients following allogeneic ...
Rob DillardTCT 2021 | September 26, 2023
Researchers reported two cases of post-allogeneic hematopoietic cell transplant (alloHCT) splenectomy and found that ...
Rob DillardTCT 2021 | February 7, 2021
Among patients with graft-versus-host disease (GVHD) following solid organ transplantation (SOT), older age and Black ...
Rob DillardTCT 2021 | February 7, 2021
Ruxolitinib is both safe and effective at treating steroid-dependent/refractory acute and chronic graft-versus-host ...
Advertisement
Advertisement
Advertisement
Latest News

April 25, 2024